B+
Bull case
25%
Probability
Target price
$21.25
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
FTRE
FortreaBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$18.53
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$14.80
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-17
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+74.5
Score
AI commentary
Post-earnings tone is cautiously constructive because guidance increased and book-to-bill remained positive, but the revenue decline, CFO uncertainty, insider selling, and unavailable analyst-revision data support monitoring rather than high conviction. Social, options, short-interest, and employee-sentiment data are unavailable; zero values represent unavailable packet data, not neutral readings.
RankAlpha Sentiment Codex - 2026-08-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-29eventQ2 execution and raised FY2026 guidanceHigh impact
Fortrea reported Q2 revenue of $678.2 million, adjusted EBITDA of $58.7 million, 1.06x book-to-bill, and increased FY2026 guidance to $2.62-$2.69 billion of revenue and $205-$220 million of adjusted EBITDA [#SEC-8K-2026-07-29].
2026-11-15catalystCFO transition and execution uncertaintyHigh impact
The stored Q2 earnings-call transcript says newly appointed CFO Jason Madlock is not currently able to act as CFO because of an ongoing restrictive-covenant proceeding involving his former employer, creating a confidence and execution risk [#PR-EARNINGS-2026-08-08].
2027-08-17catalystBacklog conversion and sustained commercial executionHigh impact
The $7.8 billion backlog and four consecutive quarters with book-to-bill above 1.0x could support further improvement if conversion remains healthy, although Q2 revenue declined year over year [#SEC-8K-2026-07-29].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-17 • Updated nightlySource: Internal modelMethodology